[ CAS No. 269396-56-7 ]

Name: 269396-56-7|(R)-3-((tert-Butoxycarbonyl)amino)-4-(3,4-dichlorophenyl)butanoic acid|98%
Brand: Ambeed
SKU: A101822
Price: 27.0 USD
Availability: InStock
Rating: 96 (28 reviews)

{[proInfo.proName]} ,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 269396-56-7

Structure of 269396-56-7 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Bulk Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 100K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 269396-56-7 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 269396-56-7 ]

SDS Specification

Alternatived Products of [ 269396-56-7 ]

Product Details of [ 269396-56-7 ]

CAS No. :	269396-56-7	MDL No. :	MFCD01860949
Formula :	C₁₅H₁₉Cl₂NO₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	WJEUUKADFJNOHW-SNVBAGLBSA-N
M.W :	348.22 g/mol	Pubchem ID :	7009786
Synonyms :

Calculated chemistry of [ 269396-56-7 ]

Physicochemical Properties

Num. heavy atoms :	22
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.47
Num. rotatable bonds :	8
Num. H-bond acceptors :	4.0
Num. H-bond donors :	2.0
Molar Refractivity :	86.17
TPSA :	75.63 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	Yes
CYP2C9 inhibitor :	Yes
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.8 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.83
Log Po/w (XLOGP3) :	3.7
Log Po/w (WLOGP) :	3.9
Log Po/w (MLOGP) :	3.25
Log Po/w (SILICOS-IT) :	3.38
Consensus Log Po/w :	3.41

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-4.0
Solubility :	0.0345 mg/ml ; 0.0000991 mol/l
Class :	Moderately soluble
Log S (Ali) :	-4.98
Solubility :	0.00366 mg/ml ; 0.0000105 mol/l
Class :	Moderately soluble
Log S (SILICOS-IT) :	-4.77
Solubility :	0.00586 mg/ml ; 0.0000168 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	2.0
Synthetic accessibility :	2.9

Safety of [ 269396-56-7 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 269396-56-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 269396-56-7 ]

[ 269396-56-7 ] Synthesis Path-Downstream 1~53

1
[ 504-78-9 ]
[ 269396-56-7 ]
[1-(3,4-dichloro-benzyl)-3-oxo-3-thiazolidin-3-yl-propyl]-carbamic acid <i>tert</i>-butyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4759 - 4762

2
[3-diazo-1-(3,4-dichloro-benzyl)-2-oxo-propyl]-carbamic acid <i>tert</i>-butyl ester [ No CAS ]
[ 269396-56-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4759 - 4762

3
N-Boc-D-3,4-dichlorophenylalanine [ No CAS ]
[ 269396-56-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4759 - 4762

4
[ 269396-56-7 ]
(R)-3-Amino-4-(3,4-dichloro-phenyl)-1-thiazolidin-3-yl-butan-1-one [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4759 - 4762

5
C₁₈H₂₃Cl₂NO₆ [ No CAS ]
[ 269396-56-7 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4759 - 4762

6
(2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carbonitrile; 4-methylbenzene-1-sulfonic acid [ No CAS ]
[ 269396-56-7 ]
tert-butyl N-[(2R)-4-[(2S,3aS,6aS)-2-cyanooctahydrocyclopenta[b]pyrrol-1-yl]-1-(3,4-dichlorophenyl)-4-oxobutan-2-yl]carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In N,N-dimethyl-formamide; at 20℃; for 20.5h;	General procedure: A solution of (3R)-3-[[(tert-butoxy)carbonyl]amino]-4-phenylbutanoic acid (compound 17a, 99.6mg, 0.357mmol) in DMF (5mL) was added HOBt (153mg, 1.134mmol) and EDCI (160mg, 0.81mmol). After stirring for 30min compound 24 (100mg, 0.324mmol) and TEA (0.16mL, 1.134mmol) were added. This solution was allowed to stir at room temperature for 20h and then the saturated NaHCO3 was added. The mixture was extracted with EtOAc and washed with saturated NaCl, dried over Na2SO4 and concentrated. The residue was purified with flash chromatography on silica gel, eluted with a mixture of PE/EA (4/1, v/v) to afford 25a (108mg, 85%) as a white solid.

Reference： [1]European Journal of Medicinal Chemistry,2014,vol. 86,p. 242 - 256

7
(2S,3aS,6aS)-octahydrocyclopenta[b]pyrrole-2-carbonitrile; 4-methylbenzene-1-sulfonic acid [ No CAS ]
[ 269396-56-7 ]
(2S,3aS,6aS)-1-[(3R)-3-amino-4-(3,4-dichlorophenyl)butanoyl]octahydrocyclopenta[b]pyrrole-2-carbonitrile [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2014,vol. 86,p. 242 - 256

8
[ 483366-11-6 ]
[ 269396-56-7 ]
tert-butyl N-[(2R)-4-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-1-(3,4-dichlorophenyl)-4-oxobutan-2-yl]carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In N,N-dimethyl-formamide; at 20℃; for 20.5h;	General procedure: A solution of (3R)-3-[[(tert-butoxy)carbonyl]amino]-4-phenylbutanoic acid (compound 17a, 108mg, 0.385mmol) in DMF (5mL) was added HOBt (166mg, 1.225mmol) and EDCI (154mg, 0.805mmol). After stirring for 30min compound 16 (100mg, 0.35mmol) and additional TEA (0.17mL, 1.225mmol) were added. This solution was allowed to stir at room temperature for 20h and then the saturated NaHCO3 was added. The mixture was extracted with EtOAc and washed with saturated NaCl, dried over Na2SO4 and concentrated. The residue was purified with flash chromatography on silica gel, eluted with a mixture of PE/EA (4/1, v/v) to afford 18a (112mg, 85%) as a white solid.

Reference： [1]European Journal of Medicinal Chemistry,2014,vol. 86,p. 242 - 256

9
[ 483366-11-6 ]
[ 269396-56-7 ]
(2S,4S)-1-[(3R)-3-amino-4-(3,4-dichlorophenyl)butanoyl]-4-fluoropyrrolidine-2-carbonitrile [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2014,vol. 86,p. 242 - 256

10
[ 852867-61-9 ]
[ 269396-56-7 ]
C₃₀H₃₆Cl₂FN₃O₃ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

11
[ 269396-56-7 ]
C₁₅H₂₁Cl₂NO₃ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

12
[ 269396-56-7 ]
C₁₅H₁₉Cl₂NO₃ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

13
[ 269396-56-7 ]
C₃₇H₄₃Cl₂FN₄O₄ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

14
[ 269396-56-7 ]
C₃₂H₃₅Cl₂FN₄O₂ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

15
[ 269396-56-7 ]
C₃₅H₄₀Cl₂FN₅O₃ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

16
[ 269396-56-7 ]
C₃₄H₃₈Cl₂FN₅O₃ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

17
[ 269396-56-7 ]
C₂₅H₂₈Cl₂FN₃O [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

18
[ 269396-56-7 ]
C₂₅H₃₀Cl₂FN₃ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

19
[ 269396-56-7 ]
C₂₈H₃₅Cl₂FN₄O [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 229 - 235

20
[ 269396-56-7 ]
tert-butyl [1-(2-[(2R)-1-(3,4-dichlorophenyl)-4-(methylamino)-4-oxobutan-2-yl]amino}-2-oxoethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]carbamate [ No CAS ]